Findings

What does this study add?

• In both studies, patients on eptinezumab 100 mg and 300 mg achieved a significant mean reduction in monthly migraine days (p< 0.05) from Day 84 to Day 1 across all tests, indicating that eptinezumab was effective from Day 1 after dosing.
• The response was sustained for 12 weeks following the initial dose.